The latest model update for Pulse Biosciences lifts the Fair Value Estimate from US$54.00 per share to about US$62.33 per share, pointing to a higher central price target in the valuation work behind this article. That change sits alongside recent analyst reports that cluster price targets between US$55 and US$73, reflecting their focus on the nanosecond pulsed field ablation platform, atrial fibrillation opportunity and new clinical partnerships. Read on to see how to track these shifting assumptions and follow the evolving Pulse Biosciences story over time.
Stay updated as the Fair Value for Pulse Biosciences shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Pulse Biosciences.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Analysts at Mizuho, Oppenheimer and Canaccord have all raised their price targets on Pulse Biosciences in recent months, with ranges now around US$55 to US$60, which signals rising conviction in the nsPFA platform and its potential applications.
-
BTIG and Freedom Capital highlight Pulse Biosciences' nanosecond pulsed field ablation technology and its speed versus microsecond systems, with BTIG pointing to European first in human data in 141 patients that showed strong procedural success out to 12 months.
-
Needham, BTIG and Canaccord all reference early clinical results and ongoing pivotal studies, and they describe the technology as differentiated within atrial fibrillation ablation, which they see as a large and potentially disruptable market.
🐻 Bearish Takeaways
-
Mizuho flags procedure volume headwinds tied to Affordable Care Act and Medicaid contraction, which could limit near term utilization and revenue ramp for Pulse Biosciences and its peers in medical devices and diagnostics.
-
Oppenheimer notes that while preliminary nsPFA data looks promising against microsecond PFA and radiofrequency, the safety and efficacy profile still needs confirmation in pivotal trials, so execution and clinical risk remain key watchpoints.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 2 risks for Pulse Biosciences. See which could impact your investment.
How This Changes the Fair Value For Pulse Biosciences
-
The Fair Value Estimate for Pulse Biosciences has moved from US$54.00 per share to about US$62.33 per share in the latest model.
-
The implied revenue growth assumption remains very large at about 218.54%, with no practical change in the updated figures.
-
The net profit margin assumption is essentially unchanged at about 12.58% in both the prior and updated model.
-
The future P/E multiple has shifted from roughly 1,158x to about 1,337x, staying at a very high level in both sets of assumptions.
-
The discount rate has moved slightly from 7.51% to about 7.51%, indicating only a minimal adjustment to the risk input.
Never Miss an Update: Follow The Narrative
Narratives link a company like Pulse Biosciences to a clear set of business milestones, clinical data and financial assumptions. They update as new trials, partnerships and regulatory decisions come through, so you can see how the story and fair value view are changing over time.
Head over to the Simply Wall St Community and follow the Narrative on Pulse Biosciences to stay up to date on:
-
How nPulse Vybrance thyroid nodule procedures, including the PRECISE BTN study, are used to support adoption and recurring disposable revenue in benign thyroid ablation.
-
Progress of the nPulse cardiac surgical clamp and nPulse 360 Catheter programs in atrial fibrillation, including IDE approval, breakthrough designation and EU feasibility work that build the case for entry into electrophysiology and cardiac surgery.
-
Key risks around reimbursement, clinical guideline inclusion, intense competition in atrial fibrillation ablation and the possibility of further equity financing if operating costs stay high relative to early revenue.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include PLSE .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
